Compounds > levodopa methyl ester
Page last updated: 2024-08-22

levodopa methyl ester and Parkinson Disease, Secondary

levodopa methyl ester has been researched along with Parkinson Disease, Secondary in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colpaert, F; Domino, EF; Marien, M; Ni, L1
Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z1
Domino, EF; Emborg-Knott, ME1
Domino, EF; Ni, L1
Domino, EF; Ni, L; Zhang, H1
Domino, EF; Greenberg, HS; Hood, TW1

Other Studies

6 other study(ies) available for levodopa methyl ester and Parkinson Disease, Secondary

ArticleYear
Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.
    Receptors & channels, 2003, Volume: 9, Issue:5

    Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Idazoxan; Levodopa; Macaca nemestrina; Parkinson Disease, Secondary; Time Factors

2003
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Annals of neurology, 1994, Volume: 35, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors

1994
MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose.
    Experimental neurology, 1998, Volume: 152, Issue:2

    Topics: Animals; Antiparkinson Agents; Carotid Arteries; Dopamine Agents; Drug Administration Schedule; Female; Follow-Up Studies; Infusions, Intra-Arterial; Levodopa; Macaca nemestrina; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Rotation

1998
Trihexyphenidyl potentiation of L-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys.
    Experimental neurology, 1998, Volume: 152, Issue:2

    Topics: Animals; Antiparkinson Agents; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Levodopa; Macaca nemestrina; MPTP Poisoning; Parkinson Disease, Secondary; Treatment Outcome; Trihexyphenidyl

1998
Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
    Experimental neurology, 1999, Volume: 158, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Interactions; Female; Levodopa; Macaca nemestrina; Motor Activity; Nicotine; Parkinson Disease, Secondary; Receptors, Dopamine D2; Rotation; Tetrahydronaphthalenes; Thiophenes

1999
Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
    Annals of the New York Academy of Sciences, 1988, Volume: 531

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic Acid; Infusion Pumps; Injections, Spinal; Levodopa; Parkinson Disease, Secondary; Pyridines; Time Factors

1988